Recent Updates
Recently added Catalysts
EUDA Positive Sentiment Score: 70/100

EUDA Health Holdings Limited Announces Amendment to Streeterville Warrant Agreement SINGAPORE

Key Takeaway: EUDA Health Holdings Limited has announced an amendment to its warrant agreement with Streeterville Capital, reducing the exercise price from $6.00 to $4.00 per share. This amendment may stimulate warrant exercises and further involvement in EUDA's growth strategy. The company operates in the non-invasive healthcare sector in Asia, targeting key markets like Singapore, Malaysia, and China, and focuses on addressing the needs of an aging population. EUDA aims to become a leader in longevity-focused healthcare solutions.

Market Sentiment Analysis

POSITIVE FACTORS

  • Amendment reduces the exercise price of the Warrant, potentially encouraging exercise.
  • Strategic focus on a growing longevity sector positions EUDA well in the healthcare market.
  • The company's commitment to addressing healthcare needs for a large demographic shift is promising.

Full Press Release Details

Health Holdings Limited Announces Amendment to Streeterville Warrant Agreement
Jan. 07, 2026 (GLOBE NEWSWIRE) - EUDA Health Holdings Limited (NASDAQ: EUDA) "EUDA" or "the Company", a
Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it has entered
into an amendment (the "Warrant Amendment") to its previously disclosed warrant agreement with Streeterville Capital, LLC
("Streeterville Capital").
on the Original Warrant Transaction
previously announced, on November 26, 2025, EUDA entered into a securities purchase agreement with Streeterville Capital, a Utah limited
liability company, for the issuance of a warrant (the "Warrant") exercisable into up to 2,000,000 newly issued ordinary shares
of EUDA for an aggregate purchase price of US$100,000. The Warrant was issued on December 4, 2025. The offer and sale of the Warrant
and the Warrant Shares were made pursuant to a prospectus supplement dated December 4, 2025, as part of a registration statement on Form
F-3 (File No. 333-282723), which was filed with the Securities and Exchange Commission on October 18, 2024 and declared effective on
November 4, 2024. The Warrant may be exercised for cash for ninety (90) days (unless extended by the parties) from the date of issuance
(the "Cash Exercise Period"). At the end of two weeks after the Cash Exercise Period has expired, Streeterville Capital will
automatically be deemed to have made a "cashless" exercise of the Warrant, and the Company will be required to issue to Streeterville
Capital one (1) ordinary share for every ten (10) outstanding Warrant Shares for no additional consideration.
December 16, 2025, EUDA and Streeterville Capital entered into the Warrant Amendment to (i) reduce the exercise price of the Warrant
from US$6.00 per share to US$4.00 per share and (ii) reduce the minimum closing price required to trigger a "Forced Exercise"
(defined in the Warrant) from US$7.50 to US$6.00. All other terms of the warrant remain unchanged.
EUDA Health Holdings Limited
Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore,
Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the
fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which
is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and
science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment
to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.
document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words,
such as the words "estimates," "projected," "expects," "envisions," "anticipates,"
"forecasts," "plans," "intends," "believes," "seeks," "may,"
"will," "should," "future," "propose" and variations of these words or similar expressions
(or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions
or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are
outside EUDA's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking
statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document.
The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.

Frequently Asked Questions

What is the recent amendment by EUDA Health Holdings?

EUDA Health Holdings amended its warrant agreement with Streeterville Capital to reduce the exercise price and minimum closing price for a forced exercise.

What are the new warrant exercise prices?

The exercise price has been lowered from US$6.00 to US$4.00 per share.

What does EUDA Health Holdings focus on?

EUDA focuses on non-invasive healthcare solutions in Singapore, Malaysia, and China.

What demographic shifts is EUDA addressing?

EUDA aims to meet the healthcare needs of over 1.8 billion people, particularly as over 30% age rapidly.

When was the original warrant issued?

The original warrant was issued on December 4, 2025.

Last updated: Jan 7, 2026